Benutzer: Gast  Login
Titel:

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.

Dokumenttyp:
Journal Article
Autor(en):
Lorenzen, Sylvie; Götze, Thorsten Oliver; Thuss-Patience, Peter; Biebl, Matthias; Homann, Nils; Schenk, Michael; Lindig, Udo; Heuer, Vera; Kretzschmar, Albrecht; Goekkurt, Eray; Haag, Georg Martin; Riera-Knorrenschild, Jorge; Bolling, Claus; Hofheinz, Ralf-Dieter; Zhan, Tianzuo; Angermeier, Stefan; Ettrich, Thomas Jens; Siebenhuener, Alexander Reinhard; Elshafei, Moustafa; Bechstein, Wolf Otto; Gaiser, Timo; Loose, Maria; Sookthai, Disorn; Kopp, Christina; Pauligk, Claudia; Al-Batran, Salah-Eddi...     »
Abstract:
PURPOSE: This trial evaluates the addition of the PD-L1 antibody atezolizumab (ATZ) to standard-of-care fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) as a perioperative treatment for patients with resectable esophagogastric adenocarcinoma (EGA). METHODS: DANTE started as multicenter, randomized phase II trial, which was subsequently converted to a phase III trial. Here, we present the results of the phase II proportion, focusing on surgical pathology and safety outcomes on an explo...     »
Zeitschriftentitel:
J Clin Oncol
Jahr:
2024
Band / Volume:
42
Heft / Issue:
4
Seitenangaben Beitrag:
410-420
Volltext / DOI:
doi:10.1200/JCO.23.00975
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/37963317
Print-ISSN:
0732-183X
TUM Einrichtung:
Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)
 BibTeX